"Over 120M patients suffer from osteoarthritis (OA) worldwide. There is no cure. Theragen is focused on finding the cure"

Technology and Science

Theragen has entered into an exclusive global licensing agreement with the University of Pennsylvania (Philadelphia) to develop a novel non-invasive form of electrical stimulation for the treatment of Osteoarthritis. Researchers at UPENN have been committed to advancing Capacitive Coupling (CC) to treat OA.

Initial published research demonstrates CC’s ability to up-regulate cartilage matrix protein production to rebuild joint cartilage, while down-regulating unwanted matrix metalloprotenases (MMP’s) which have been identified as central to degradation of articular cartilage. This ‘one-two punch’ holds promise in the treatment of osteoarthritic joints, and stands at the center of Theragen’s ongoing R&D efforts.

Capacitive Coupling

Capacitive Coupling is a safe and proven non-invasive electrical therapy first approved in 1986 for treatment of non-union fractures, and then as an adjunct to spine fusion procedures in 2000. More than 100,000 patients have been treated with CC for these indications, and the safety profile remains exemplary.

Currently, non-invasive Capacitive Coupling electrical therapy cleared for challenging fractures and as an adjunct to spine fusions is delivered by wafer-thin skin electrodes applied to the local anatomy. It is powered by a small, easy-to-wear signal generator which delivers therapeutic electrical energy in a specific wavelength, amplitude, frequency and duty cycle to positively influence healing processes. Theragen seeks to develop a CC signal specialized for the treatment of Osteoarthritis. The treatment is expected to be delivered round-the-clock for healing results, and will be designed to be powered by a conveniently sized, portable control unit to support unrestricted mobility and reusable skin electrodes which can be removed and re-applied as necessary to accommodate bathing, showering, etc.